Genome Editing Market is Expected to Reach $9,078.6 Million by 2026

ABOUT THIS REPORT

OVERVIEW

Genome Editing Market is valued at USD XX million in 2019 and is expected to reach USD 9,078.6 million by the end of 2026.

Bizlytik analysts forecast the global Genome Editing market to grow at a CAGR of 14.2% during the forecast period, according to their latest market research report.

Genome editing is used to modify DNA within a cell. Genome editing can be used to add, alter, and remove DNA in the genome. Genome editing helps to change the DNA in cells or organisms to understand their biology. It is used to modify human blood cells to treat conditions, including leukaemia, AIDS, and treat other infection. Genome editing is also used in agriculture to modify crops to improve their yields and resistance to disease and drought.

CRISPR/Cas9, ZNF and TALEN are used in gene therapy to cure lethal diseases and genetic diseases through gene modification. Biotech and Pharma companies are adopting these technologies for better disease management as well as the development of personalized medicine. CRISPR/Cas9 system has the potential to treat a broad range of disorders including cancer, viral infection and genetic diseases. Many vendors are using the CRISPR/Cas9 system to enter into the niche genome editing market. TALEN are used to treat X-linked severe combined immunodeficiency, lymphoblastic leukaemia. This technology has generated custom T-cells that are useful to treat cancer, and ZNF produces an HIV-resistant T-cell population and is expected to treat HIV in individuals. The companies and research institute are collaborating to develop new medicines for cancer using CRISPR technology. For instance, AstraZeneca has collaborated with Cancer Research UK to introduce a center of excellence in cancer modelling, genetic screening and big data processing to accelerate the discovery of new cancer medicines. The Functional Genomics Centre will develop CRISPR technology to understand the biology of cancer better, creating biological models that are more reflective of human disease, and advancing computational approaches to analyze big datasets better.

CRISPR, TALEN, Zinc-Finger Nuclease (ZFN), Meganucleases, and Other are covered in the Type segment of the market scope, the Application segment is categorized into Cell Line Engineering, Plant Genetic Engineering, and Animal Genetic Engineering, and the End user segment is divided into Pharma and Biotech Companies, CRO (Contract Research Organizations), Research Institutes, and Others. The report covers value of the global market by Type, Application and End-user.

The market value of CRISPR was USD XX Million in 2019, and it is expected to reach USD XX Million by 2026, growing at a CAGR of 14.7% during 2020-2026. The strategic collaboration by the companies for research and development of new therapy with CRISPR would propel the growth of the segment.

North America, Europe, Asia Pacific, South America, and Middle East & Africa are taken into consideration at the global Genome Editing Value figures. While North America is further categorized into enhancing United States, Canada, and Mexico, Europe is split into the United Kingdom, Germany, France, Italy, and Rest of Europe. Asia-Pacific covers India, China, Japan, South Korea, and Rest of Asia Pacific in its scope. South America is bifurcated into Brazil, Argentina, and Rest of South America, with Middle East & Africa involving GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America Genome Editing market was USD XX Million in 2019, and it is predicted to reach USD XX Million by 2026, growing at a CAGR of 15.6% during the forecast period. The increasing clinical studies by the companies on genome editing, strategic collaboration between companies to conduct research and development of new therapy with genome editing, and government initiative to provide support and funding to the companies for testing and development of new therapy are some of the factors that would improve the growth prospects of the market.

Major players operating in the Genome Editing industry include Thermo Fisher Scientific Inc., Merck Group, New England Biolabs, Inc., GenScript USA Inc., Integrated DNA Technologies Inc., Horizon Discovery Group plc, Origene Technologies Inc., Sangamo Biosciences, Inc., Transposagen Biopharmaceuticals, Inc., CRISPR Therapeutics.

Formation of strategic collaborations and government funding to the companies are the few business strategies adopted by the key companies, with a focus on maintaining a competitive advantage over others. The companies are focused on expanding business activities on a global scale.